2 results
Approved WMOCompleted
Primary* To evaluate the effect of RO7049665 on time to relapse following forced CCS tapering as measured by the hazard ratio between 7.5 mg RO7049665 and placebo.Secondary* To assess changes in alanine aminotransferase (ALT), aspartate…
Approved WMOPending
Main objective:•To compare the progression-free survival of imlunestrant (Arm A) to the standard comparator of Investigator's Choice Endocrine Therapy of either fulvestrant or exemestane (Arm B) in the ITT population•To compare the PFS of Arm…